Armand, P. Et Al. 2018. Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. 60th Annual Meeting of the American-Society-of-Hematology (ASH) , (California, United States Of America).

Armand, P., Rodig, S. J., Melnichenko, V., Thieblemont, C., Bouabdallah, K., Tumyan, G., ... ÖZCAN, M.(2018). Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies . 60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America

Armand, Philippe Et Al. "Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies," 60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 2018

Armand, Philippe Et Al. "Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies." 60th Annual Meeting of the American-Society-of-Hematology (ASH) , California, United States Of America, 2018

Armand, P. Et Al. (2018) . "Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies." 60th Annual Meeting of the American-Society-of-Hematology (ASH) , California, United States Of America.

@conferencepaper{conferencepaper, author={Philippe Armand Et Al. }, title={Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies}, congress name={60th Annual Meeting of the American-Society-of-Hematology (ASH)}, city={California}, country={United States Of America}, year={2018}}